55 results about "Torsemide" patented technology

There is provided an injection with torasemide as the main active ingredient in the invention, the preparing method of the injection is also included in the invention. The stability of the injection in the invention has been greatly improved. There is solubilizing agent and stabilizer in the preparation, the pH value is 9.0 or larger. The preparing method includes the following steps: adding 1-50% (by weight) of solubilizing agent to certain amount of injecting water; adding torasemide to the water, after it is completely dissolved, adding 0.1-5% part of stabilizer; adding water to requested amount and stirring uniformly; adding activated char to adsorb for 30min at high temperature; decarbonizing and filtering; adding medically used alkali to regulate the ph value to 9.0 or larger; aseptically filtering; after the assay is approved, packaging, degerming and stocking. The advantages of the invention include: high stability, short preparing time, low cost, no haemolyticus, blood vessel stimulus and allerfic response, low growing speed of relative substances.

The invention discloses a method for purification of torasemide and preparation of big crystal form, which is characterized in that Torasemide crude is dissolved in acidulous solvent to raise the temperature to 85-100 DEG C; the mixture is stirred for dissolved clarification and is decolorized and filtered; the temperature of filtrate is slowly lowered to 5-30 DEG C for crystallization; crystal is obtained by filtering and separating; and then the obtained product is dried at the temperature of 50-70 DEG C to obtain purified Torasemide crystal. The invention has the advantage of simple processing method and can obtain the crystal of which the purity is 99% and average grain diameter is 50-350 mu m by dissolving, crystallizing and purifying.

The invention relates to a pharmaceutical composition containing a torasemide odor masking composition and a preparation method thereof. The invention is characterized in that flavoring agent in the torasemide odor masking composition is selected from gelatin, mannite and aspartame; and the pharmaceutical composition exists in the form of powder or grains, can lead to good preparation stability and covers the bitterness, has good mouth taste, and is fast to beak down and absorb and convenient to carry.

The invention provides a torasemide compound and a new preparation method thereof, and the method comprises the following steps: (1) processing the torasemide raw material by alkali metals or alkaline earth metal alkane oxides with the presence of an appropriate solvent or solvent mixture under an alkaline and heating condition; (2) adjusting the pH value by an appropriate acid; (3) adsorbing the torasemide by strong basic ion exchange resin and eluting the product; (4) adjusting the pH value by an appropriate acid to obtain a three-stage purified torasemide. The preparation method of torasemide improves the product quality of the preparation, reduces the toxic and side effects, is simple and easy to operate, and is applicable to large-scale industrial production.

The invention relates to a torasemide pharmaceutical composition with stabilization and safety for injection and its preparation method, especially relates to the torasemide pharmaceutical composition used for patients with requirement of rapid diuresis or congestive cardiac failure without oral diuresis, cirrhosis ascites, oedema caused by kidney diseases, the torasemide pharmaceutical composition is an injection preferably. The pharmaceutical composition is composed of active component torasemide, ethanol and polysorbate 80. The torasemide pharmaceutical composition for injection possesses stable pH value and low impurity content, and is capable of effectively raising the treatment effect of the products, minimizing the side reaction, raising the yield, reducing the cost and creating higher benefit.

The invention discloses a method for optimizing a freeze-drying curve of a torasemide freeze-drying preparation for injection. According to the technical scheme, the characters of dried frozen aquatic products are improved by selecting reasonable pre-freezing and sublimating temperatures. The quality standards meet various indexes specified in National Drug Standards. The method disclosed by the invention has the advantages of stable characters of the dried frozen aquatic products, small auxiliary material addition amount, short freeze-drying time and the like.

The invention relates to a torasemide freeze-dried powder injection and a preparation process thereof. The freeze-dried powder injection comprises 1 part by weight of torasemide, 1 part by weight of sodium bicarbonate, 8 to 17 parts by weight of mannitol, an appropriate amount of a pH regulator, and the pH value of the freeze-dried composition aqueous solution is adjusted to be 8.5 to 9.5. The torasemide freeze-dried powder injection prepare by that method according to the prescription of the invention has the advantages of short redissolution time, low moisture content, good appearance and high stability, and is very suitable for clinical use.

Disclosed herein are treatments for diseases such as sleep apnea, hyperuricemia, autistic spectrum disorder (ASD) and other brain disorders using controlled-release (CR, e.g., extended-release (ER) or prolonged-release (PR)) oral dosage formulations comprising an effective amount of Torsemide.

The invention provides a solid preparation of Torasemide liposome, which is prepared from the following raw materials and auxiliaries in parts by weight: 10 parts of Torasemide, 40 to 100 parts of soybean lecithin, 5 to 40 parts of cholesterin, 4 to 20 parts of sodium glycocholate, 60 to 200 parts of sorbitol and 5 to 20 parts of soyasterol. The solid preparation provided by the invention has high dissolubility, high stability, simple preparation method, high envelope rate, uniform particle size and long remaining time in body, thus the quality of preparation product is enhanced, the bioavailability is raised and the toxic and side effects are reduced.

The invention provides a method for qualitatively and quantitatively detecting torasemide illegally added into food and application. The method comprises the following steps: preparing a to-be-detected sample and a standard solution of torasemide; respectively measuring theto-be-detected sample and the standard solution by adopting a high performance liquid chromatography-tandem mass spectrometer; recording the chromatographic retention time of each compound in the food sample and the standard solution, taking the percentage relative to the strongest ion abundance as the relative abundance of a qualitative ion pair, and recording the relative ion abundance of corresponding components in the to-be-detected sample and the standard solution with equivalent concentration; and when a chromatographic peak consistent with the chromatographic peak retention time of the torasemide standard substance is detected in the sample to be detected, determining that the corresponding compound and the content are detected in the sample to be detected. The detection method disclosed by the invention is simple, convenient and rapid in pretreatment, strong in specificity and high in sensitivity, can be used for simultaneously carrying out qualitative and quantitative analysis on the torasemide in foods such as tablet candies, biscuits, drinks, oral liquid and tea drinks, and can be applied to screening illegal addition of the torasemide in food safety supervision.

The present invention relates to a veterinary pharmaceutical composition containing torasemide to be used for treating cardiac failure. The torasemide is administered in a daily dose of 0.02 mg/kg to 0.1 mg/kg during long-term treatment.

The invention belongs to the technical field of medicines, and particularly relates to a torasemide compound. The torasemide compound obtained in the invention has the advantages of small relevant substances, high purity, good stability and unobvious moisture absorption and weight increment even under the condition of high humidity.

The invention discloses a slow release tablet containing active ingredient of torasemide, which comprises torasemide, slow release material and other auxiliary materials by the weight ratio of 1 : 0.2-20 : 10-200, preferably 1 : 0.5-10 : 20-100. The prepared slow release tablet is suitable for patients of hypertension.

The invention relates to compositions and methods for improving memory and related functions as alertness, attention, concentration, learning, and language processing. More particularly, the invention relates to compositions comprising at least two drugs selected from cinacalcet, baclofen, acamprosate, mexiletine, sulfisoxazole and torasemide useful to enhance memory and related functions in healthy subjects or subjects suffering from conditions or disorders having a negative impact on their memory.

The invention belongs to the technical field of medicine, and specifically relates to a torasemide compound and a preparation method thereof. The provided novel torasemide crystal form has the advantages of high purity (the maximal impurity content is less than 0.05%), and good stability. Moreover, the preparation method has a good repeatability, and the purity and crystal form can be well repeated when the preparation method is amplified to a pilot scale. The invention further relates to an application of the novel torasemide crystal form in preparation of drugs for treating medium and heavy edema caused by heart failure, kidney failure, cirrhosis ascites, encephaledema, and the like.

The invention relates to a novel torasemide impurity and a preparation method thereof. The invention relates to a novel torasemide impurity, namely TL-Imp07: 4-m-toluene amino-N-[(4-m-toluene aminopyridine-3-yl) sulfonyl] pyridine-3-sulfonamide. The preparation method of the TL-Imp07 comprises the steps of carrying out condensation and ammoniation reactions on 4-chloro-3-pyridine sulfonamide. The impurity is novel in structure, is reported for the first time and has great significance on quality control of torasemide crude drugs and preparations. Meanwhile, the preparation method has the advantages of being simple, convenient to operate, high in product purity and the like and can be applied to research of impurity reference substances of torasemide.